证券代码：002102 证券简称：能特科技 公告编号：2025-091 湖北能特科技股份有限公司 关于回购公司股份比例达到 1%暨回购进展情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 湖北能特科技股份有限公司（以下简称"公司"）于 2025 年 7 月 2 日召开 了第七届董事会第三十三次会议、第七届监事会第二十六次会议，于 2025 年 7 月 18 日召开了 2025 年第五次临时股东大会，审议通过了《关于回购股份并注销 的议案》，同意公司使用自有资金及自筹资金以资金总额不低于人民币 30,000 万元（含），不超过人民币 50,000 万元（含），回购价格不超过人民币 4.70 元/ 股（含），通过深圳证券交易所交易系统以集中竞价交易方式回购部分公司股份， 实施期限为自公司股东大会审议通过回购方案之日起 12 个月内（即 2025 年 7 月 19 日至 2026 年 7 月 18 日），具体回购股份的数量以回购方案实施完毕时实 际回购的股份数量为准。本次回购股份将全部用于注销并相应减少注册资本。具 体内容详见公司于 2025 年 7 月 ...

Group 1 - The company, Nengte Technology, announced a share buyback plan, having repurchased a total of 33,503,900 shares as of September 4, 2025, which represents 1.35% of its total share capital of 2,475,626,790 shares [1] - The highest transaction price for the repurchased shares was 4.39 yuan per share, while the lowest was 3.97 yuan per share [1] - The total amount spent on the share buyback reached 136.9582 million yuan, excluding transaction fees [1]

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 湖北能特科技股份有限公司（以下简称"公司"）于 2025 年 7 月 2 日召开 了第七届董事会第三十三次会议、第七届监事会第二十六次会议，于 2025 年 7 月 18 日召开了 2025 年第五次临时股东大会，审议通过了《关于回购股份并注销 的议案》，同意公司使用自有资金及自筹资金以资金总额不低于人民币 30,000 万元（含），不超过人民币 50,000 万元（含），回购价格不超过人民币 4.70 元/ 股（含），通过深圳证券交易所交易系统以集中竞价交易方式回购部分公司股份， 实施期限为自公司股东大会审议通过回购方案之日起 12 个月内（即 2025 年 7 月 19 日至 2026 年 7 月 18 日），具体回购股份的数量以回购方案实施完毕时实 际回购的股份数量为准。本次回购股份将全部用于注销并相应减少注册资本。具 体内容详见公司于 2025 年 7 月 19 日披露的《回购报告书》（公告编号：2025-080）。 证券代码：002102 证券简称：能特科技 公告编号：2025-091 湖北能特科技股 ...

格隆汇9月4日丨能特科技(002102.SZ)公布，截至2025年9月4日，公司通过股票回购专用证券账户以集 中竞价交易方式累计回购股份数量为33,503,900股，累计回购的股份数量占公司总股本(2,475,626,790股) 的1.35%，最高成交价为4.39元/股，最低成交价为3.97元/股，成交总金额为13,695.82万元(不含交易费 用)。 ...

（文章来源：证券日报） 证券日报网讯 9月2日晚间，能特科技发布公告称，截至2025年8月31日，公司通过股票回购专用证券账 户以集中竞价交易方式累计回购股份数量为17，254，600股，累计回购的股份数量占公司总股本（2， 475，626，790股）的0.70%。 ...

格隆汇9月2日丨能特科技(002102.SZ)公布，截至2025年8月31日，公司通过股票回购专用证券账户以集 中竞价交易方式累计回购股份数量为17,254,600股，累计回购的股份数量占公司总股本(2,475,626,790股) 的0.70%，最高成交价为4.39元/股，最低成交价为3.97元/股，成交总金额为6,999.43万元(不含交易费 用)。 ...

证券代码：002102 证券简称：能特科技 公告编号：2025-090 湖北能特科技股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 湖北能特科技股份有限公司（以下简称"公司"）于 2025 年 7 月 2 日召开 了第七届董事会第三十三次会议、第七届监事会第二十六次会议，于 2025 年 7 月 18 日召开了 2025 年第五次临时股东大会，审议通过了《关于回购股份并注销 的议案》，同意公司使用自有资金及自筹资金以资金总额不低于人民币 30,000 万元（含），不超过人民币 50,000 万元（含），回购价格不超过人民币 4.70 元/ 股（含），通过深圳证券交易所交易系统以集中竞价交易方式回购部分公司股份， 实施期限为自公司股东大会审议通过回购方案之日起 12 个月内（即 2025 年 7 月 19 日至 2026 年 7 月 18 日），具体回购股份的数量以回购方案实施完毕时实 际回购的股份数量为准。本次回购股份将全部用于注销并相应减少注册资本。具 体内容详见公司于 2025 年 7 月 19 日披露的《回购报 ...

Core Insights - Nengte Technology (002102.SZ) reported a significant increase in net profit for the first half of 2025, achieving a net profit of 339 million yuan, a year-on-year growth of 496.36% [1][2] - The company's total revenue for the same period was 5.229 billion yuan, reflecting a year-on-year decline of 16.09% [1] - The substantial growth in net profit is attributed to the strong performance of its subsidiary, Nengte Technology Co., which generated approximately 447 million yuan in profit from its vitamin E and pharmaceutical intermediate businesses [2] Financial Performance - For the first half of 2025, Nengte Technology reported total revenue of 5.229 billion yuan, down 16.09% year-on-year [1] - The net profit attributable to shareholders reached 339 million yuan, marking a 496.36% increase compared to the previous year [1] - The company's net profit after deducting non-recurring gains and losses was 411 million yuan, showing a remarkable growth of 759.36% [1] - The net cash flow from operating activities was 225 million yuan, an increase of 12.28% year-on-year [1] Business Operations - Nengte Technology's core business includes pharmaceutical intermediates, vitamin E and its intermediates, and plastic trade e-commerce [1] - The company has been focusing on strengthening its production chains for key products such as Montelukast sodium intermediates and Rosuvastatin intermediates to enhance its competitive edge [2] - Continuous research and development efforts are being made to cultivate new pharmaceutical intermediate varieties, enriching the company's product structure and promoting multi-variety development [2]

Core Viewpoint - Nengte Technology (002102) reported a significant increase in net profit for the first half of 2025, with a year-on-year growth of 496.36%, despite a decline in total revenue [1] Financial Performance Summary - Total revenue for the first half of 2025 was 5.229 billion yuan, a decrease of 16.09% compared to the same period in 2024 [1] - Net profit attributable to shareholders reached 339 million yuan, up 496.36% year-on-year [1] - The gross profit margin was 1.93%, down 10.08% year-on-year, while the net profit margin increased to 6.62%, up 564.69% [1] - Total expenses (selling, administrative, and financial) amounted to 63.6463 million yuan, accounting for 1.22% of revenue, an increase of 18.65% [1] - Earnings per share rose to 0.13 yuan, a 496.3% increase year-on-year [1] Key Financial Changes - Cash and cash equivalents decreased by 25.31% due to a reduction in trade business scale [3] - Long-term equity investments increased by 15.81% due to significant performance improvements in joint ventures [3] - Short-term borrowings rose by 30.96% at the end of the reporting period [3] - Sales expenses increased by 18.75% due to higher costs associated with specific sales activities [3] - Financial expenses increased by 36.81% due to a significant reduction in interest income [4] Business Overview - Nengte Technology's main business includes pharmaceutical intermediates and vitamin E, with a focus on research, production, and sales [6] - The company has established successful collaborations with major global firms, enhancing its market position [6] - The vitamin E segment is expected to contribute significantly to profits, with projections indicating a minimum profit of 44 million yuan from this segment by mid-2025 [6]

Core Viewpoint - The company, Nengte Technology, has provided an update regarding the approval process for its raw material drug licenses, indicating that after approval, the raw materials must be associated with formulation companies for further testing, which typically takes 3 to 8 months [1] Group 1 - The company confirmed that the approval of raw material drug licenses is subject to pharmaceutical management regulations and requires collaboration with formulation enterprises [1] - The testing period for the formulation companies using the approved raw materials is generally between 3 to 8 months [1] - The company will disclose its business development status in accordance with relevant information disclosure rules and encourages stakeholders to pay attention to future regular reports [1]